IMVT
Immunovant Inc (IMVT)
Healthcare • NASDAQ • $38.22+1.59%
- Symbol
- IMVT
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $38.22
- Daily Change
- +1.59%
- Market Cap
- $7.26B
- Trailing P/E
- N/A
- Forward P/E
- -14.51
- 52W High
- $36.29
- 52W Low
- $14.32
- Analyst Target
- $45.76
- Dividend Yield
- N/A
- Beta
- 0.79
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Company websiteResearch IMVT on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.